Business headlines from the Apex backend, organized by sectors and major public companies for faster market scanning.
A new market commentary points to a payout ratio that can look alarming, but argues investors should focus on the underlying earnings or cash-flow pressures behind Pfizer’s dividend.
THE APEX TIMES
THE APEX TIMES
A new market-focused article uses a $1,000 “what if” investment in Caterpillar to illustrate how long-horizon returns can compound, while noting that outcomes depend on what an investor assumes about dividends and timing.
THE APEX TIMES
Netflix’s Newsroom said it has released a trailer for the second season of “The Ramparts of Ice,” framing the update as an escalation of emotion and relationships as the series returns.
THE APEX TIMES
A draft specification for SHRINCS, a post-quantum signature scheme aimed at Bitcoin transaction authorization, has been circulating alongside references to a Ripple-focused hackathon that includes Mastercard in its materials.
THE APEX TIMES
The payments network company said it is expanding tools designed to help clients identify and address vulnerabilities, framing the move as part of the broader shift toward securing systems in the age of artificial intelligence.
THE APEX TIMES
A Yahoo Finance report framed Microsoft’s expanding artificial intelligence effort as another test of whether demand for AI tools and infrastructure can show up directly in Azure growth and related profitability.
THE APEX TIMES
Investors focused on Target’s reported second-quarter 2026 results, its raised full-year guidance, and the completion of a multi-year share repurchase program, alongside an expansion of its beauty offerings through a new “beauty studio” concept.
THE APEX TIMES
Chevron says it is expanding into nuclear fusion technology, aligning with a wider industry push toward commercial fusion power. What the company wants from the effort is less about near-term revenues and more about securing options in a future energy market, experts say.
THE APEX TIMES
A new set of findings highlighted by Yahoo Finance points to a potentially larger weight-loss opportunity for Eli Lilly’s obesity medicines, with implications for payer coverage decisions.
